S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
3 Top-Rated, Oversold Industry Giants
Laser breakthrough could send stock soaring 2,467% (Ad)
PayPal Keeps Getting Cheaper; Should You Load Up?
What's Really Behind The FTC's Lawsuit Targeting of Amazon?
Laser breakthrough could send stock soaring 2,467% (Ad)
Delta Hopes to Soar Again with Customer Loyalty Tweaks
Is the Grinch Stealing This Year's Holiday Season Jobs?
Laser breakthrough could send stock soaring 2,467% (Ad)
The Next Stage Of Google’s Rally Just Started
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
3 Top-Rated, Oversold Industry Giants
Laser breakthrough could send stock soaring 2,467% (Ad)
PayPal Keeps Getting Cheaper; Should You Load Up?
What's Really Behind The FTC's Lawsuit Targeting of Amazon?
Laser breakthrough could send stock soaring 2,467% (Ad)
Delta Hopes to Soar Again with Customer Loyalty Tweaks
Is the Grinch Stealing This Year's Holiday Season Jobs?
Laser breakthrough could send stock soaring 2,467% (Ad)
The Next Stage Of Google’s Rally Just Started
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
3 Top-Rated, Oversold Industry Giants
Laser breakthrough could send stock soaring 2,467% (Ad)
PayPal Keeps Getting Cheaper; Should You Load Up?
What's Really Behind The FTC's Lawsuit Targeting of Amazon?
Laser breakthrough could send stock soaring 2,467% (Ad)
Delta Hopes to Soar Again with Customer Loyalty Tweaks
Is the Grinch Stealing This Year's Holiday Season Jobs?
Laser breakthrough could send stock soaring 2,467% (Ad)
The Next Stage Of Google’s Rally Just Started
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
3 Top-Rated, Oversold Industry Giants
Laser breakthrough could send stock soaring 2,467% (Ad)
PayPal Keeps Getting Cheaper; Should You Load Up?
What's Really Behind The FTC's Lawsuit Targeting of Amazon?
Laser breakthrough could send stock soaring 2,467% (Ad)
Delta Hopes to Soar Again with Customer Loyalty Tweaks
Is the Grinch Stealing This Year's Holiday Season Jobs?
Laser breakthrough could send stock soaring 2,467% (Ad)
The Next Stage Of Google’s Rally Just Started
Nike, Amicus Therapeutics rise; Vail Resorts, Hess fall, Friday, 9/29/2023

Mineralys Therapeutics (MLYS) Competitors

$9.51
+0.21 (+2.26%)
(As of 09/29/2023 ET)
Compare
Today's Range
$9.37
$9.73
50-Day Range
$9.30
$14.92
52-Week Range
$8.87
$21.98
Volume
102,672 shs
Average Volume
191,663 shs
Market Capitalization
$388.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.00

MLYS vs. NRIX, OCS, LQDA, PROC, MRNS, ICPT, EWTX, LYEL, ORIC, and IGMS

Should you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include Nurix Therapeutics (NRIX), Oculis (OCS), Liquidia (LQDA), Procaps Group (PROC), Marinus Pharmaceuticals (MRNS), Intercept Pharmaceuticals (ICPT), Edgewise Therapeutics (EWTX), Lyell Immunopharma (LYEL), ORIC Pharmaceuticals (ORIC), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical preparations" industry.

Mineralys Therapeutics vs.

Mineralys Therapeutics (NASDAQ:MLYS) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and community ranking.

Nurix Therapeutics received 27 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 64.81% of users gave Nurix Therapeutics an outperform vote.

CompanyUnderperformOutperform
Mineralys TherapeuticsOutperform Votes
8
100.00%
Underperform Votes
No Votes
Nurix TherapeuticsOutperform Votes
35
64.81%
Underperform Votes
19
35.19%

In the previous week, Mineralys Therapeutics and Mineralys Therapeutics both had 2 articles in the media. Mineralys Therapeutics' average media sentiment score of 1.61 beat Nurix Therapeutics' score of 1.24 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mineralys Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Nurix Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Mineralys Therapeutics has higher earnings, but lower revenue than Nurix Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mineralys TherapeuticsN/AN/A-$29.80MN/AN/A
Nurix Therapeutics$38.63M9.81-$180.36M-$2.97-2.65

Mineralys Therapeutics currently has a consensus target price of $36.00, indicating a potential upside of 278.55%. Nurix Therapeutics has a consensus target price of $27.44, indicating a potential upside of 249.17%. Given Mineralys Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Mineralys Therapeutics is more favorable than Nurix Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mineralys Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Nurix Therapeutics
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89

61.7% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 90.4% of Nurix Therapeutics shares are owned by institutional investors. 7.2% of Nurix Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Mineralys Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -258.37%. Mineralys Therapeutics' return on equity of -27.88% beat Nurix Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Mineralys TherapeuticsN/A -27.88% -16.21%
Nurix Therapeutics -258.37%-53.36%-39.44%

Summary

Mineralys Therapeutics beats Nurix Therapeutics on 8 of the 13 factors compared between the two stocks.


Get Mineralys Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MLYS vs. The Competition

MetricMineralys TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$379.97M$5.72B$4.40B$6.29B
Dividend YieldN/A2.75%2.55%7.65%
P/E RatioN/A5.24120.4312.23
Price / SalesN/A145.592,998.4655.41
Price / CashN/A22.0594.04103.27
Price / BookN/A3.753.774.67
Net Income-$29.80M$201.12M$122.26M$186.31M
7 Day Performance-11.45%0.87%1.09%0.43%
1 Month Performance-25.99%-8.85%-4.25%-6.08%
1 Year PerformanceN/A4.49%8.53%6.47%

Mineralys Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NRIX
Nurix Therapeutics
1.8114 of 5 stars
$8.52
+0.5%
$27.44
+222.1%
-39.0%$410.66M$38.63M-2.87297Upcoming Earnings
Positive News
OCS
Oculis
1.9356 of 5 stars
$11.05
-3.4%
$33.40
+202.3%
N/A$416.28M$960,000.000.0028
LQDA
Liquidia
2.3276 of 5 stars
$6.31
+0.6%
$13.75
+117.9%
+19.6%$408.51M$15.94M-8.1963Analyst Report
Gap Up
PROC
Procaps Group
1.6844 of 5 stars
$3.80
+7.3%
$4.50
+18.4%
-44.8%$428.72M$406.09M5.765,500Positive News
Gap Up
MRNS
Marinus Pharmaceuticals
2.4326 of 5 stars
$7.84
+9.5%
$21.50
+174.4%
+14.7%$396.53M$25.48M-52.23151
ICPT
Intercept Pharmaceuticals
2.1445 of 5 stars
$18.71
+79.2%
$22.36
+19.5%
+13.0%$436.22M$306.48M2.93341Analyst Downgrade
Short Interest ↑
Analyst Revision
News Coverage
High Trading Volume
EWTX
Edgewise Therapeutics
1.637 of 5 stars
$6.11
+3.2%
$27.00
+341.9%
-40.3%$387.74MN/A-4.5374
LYEL
Lyell Immunopharma
2.0496 of 5 stars
$1.54
+6.2%
$6.25
+305.8%
-80.2%$386.59M$84.68M-1.83274Positive News
ORIC
ORIC Pharmaceuticals
2.1579 of 5 stars
$7.04
-6.9%
$15.00
+113.1%
+86.7%$383.89MN/A-3.2389News Coverage
Gap Down
IGMS
IGM Biosciences
2.624 of 5 stars
$7.72
+5.5%
$23.60
+205.7%
-57.0%$450.62M$1.07M-1.46289

Related Companies and Tools

This page (NASDAQ:MLYS) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -